Literature DB >> 16216395

Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models.

Nancy Gore Saravia1, Blanca Escorcia, Yaneth Osorio, Liliana Valderrama, Darren Brooks, Lourdes Arteaga, Graham Coombs, Jeremy Mottram, Bruno Luis Travi.   

Abstract

This study demonstrates that deletion of cysteine proteinase (CP) genes diminishes pathogenicity of Leishmania mexicana in non-murine experimental host models while preserving immunogenicity. Both cpb and cpa/cpb-deficient lines induced delayed disease onset, smaller lesions and lower parasite burden in hamsters. cpa/cpb-deficient L. mexicana grew more slowly as promastigotes and presented lower infectivity and growth in human mononuclear phagocytic host cells. Protection against homologous challenge comparable to that induced by infection with the virulent wild-type (WT) L. mexicana strain was achieved in the highly susceptible hamster model by immunization with 1000 cpb-deficient promastigotes. CP-deficient L. mexicana elicited significantly lower levels of Th2-associated cytokines IL-10 and TGF-beta than the WT in the primary lesion of hamsters. These findings support the feasibility of using genetically attenuated live Leishmania to achieve protective immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216395     DOI: 10.1016/j.vaccine.2005.05.045

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

Review 1.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

2.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05

Review 3.  Modulation of dendritic cell function by Leishmania parasites.

Authors:  Lynn Soong
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

4.  Proteinases as virulence factors in Leishmania spp. infection in mammals.

Authors:  Mariana Silva-Almeida; Bernardo Acácio Santini Pereira; Michelle Lopes Ribeiro-Guimarães; Carlos Roberto Alves
Journal:  Parasit Vectors       Date:  2012-08-07       Impact factor: 3.876

5.  Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system.

Authors:  Yaneth Osorio; Bruno L Travi; Adam R Renslo; Alex G Peniche; Peter C Melby
Journal:  PLoS Negl Trop Dis       Date:  2011-02-15

6.  Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation.

Authors:  Javier Carrión; Cristina Folgueira; Manuel Soto; Manuel Fresno; Jose M Requena
Journal:  Parasit Vectors       Date:  2011-07-27       Impact factor: 3.876

7.  Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites.

Authors:  Angamuthu Selvapandiyan; Ranadhir Dey; Sreenivas Gannavaram; Ines Lakhal-Naouar; Robert Duncan; Poonam Salotra; Hira L Nakhasi
Journal:  J Trop Med       Date:  2011-09-06

8.  Protective immunity and vaccination against cutaneous leishmaniasis.

Authors:  Ifeoma Okwor; Zhirong Mou; Dong Liu; Jude Uzonna
Journal:  Front Immunol       Date:  2012-05-29       Impact factor: 7.561

Review 9.  Transgenic Leishmania and the immune response to infection.

Authors:  L Beattie; K J Evans; P M Kaye; D F Smith
Journal:  Parasite Immunol       Date:  2008-02-04       Impact factor: 2.280

10.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.